Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant.
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D000939:Epitopes; D005260:Female; D024522:Genes, BRCA2; D006086:Graft vs Host Disease / Q000235:genetics; D020544:Graft vs Leukemia Effect / Q000235:genetics; D015234:HLA-A Antigens / Q000235:genetics*; D059871:HLA-A24 Antigen; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology
D000939:Epitopes; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D015778:Minor Histocompatibility Antigens